Conference Coverage

Drugs for Progressive MS Could Target Multiple Disease Mechanisms


 

References

The results indicate that neurologists may now have a marker to track this aspect of MS pathology, she continued. Diffuse and focal meningeal inflammation is present within days to weeks of initial presentation. This inflammation increases the likelihood of cortical demyelination and may contribute to disease progression. In a cohort of patients with early MS, meningeal inflammation was associated with subpial demyelination, similar to the association in chronic MS.

Mainero et al found that sparse areas of abnormality within the upper 25% of the brain tissue correspond with focal myelin loss or iron loss. Deeper areas of the cortex have more extensive involvement (ie, prolonged T2), and these changes are strongly associated with Expanded Disability Status Scale score. This process begins early and is not associated with white matter lesion burden, thus “highlighting the importance of this pathology to some elements of disease progression,” said Dr. Lucchinetti.

Deep Gray Matter Damage

Damage to deep gray matter in MS is focused in the caudate and the hypothalamus. As the disease progresses, it may involve the deep gray matter more extensively. Atrophy of the third ventricle is one potential way to measure the degree to which MS affects the thalamus. This atrophy seems to be associated with cognitive decline, motor deficits, and fatigue. It correlates with cortical demyelination, but not white matter demyelination.

Current approved therapies “are really targeting what we can see, [such as] inflammation and white matter plaques, but there’s much more going on,” concluded Dr. Lucchinetti.

Erik Greb

Pages

Recommended Reading

Brain atrophy may be a clinically relevant measure in PPMS: Data from INFORMS
MDedge Neurology
Stem cell therapy for MS: Steady progress but not ready for general use
MDedge Neurology
Natalizumab May Increase Risk of JCV Seroconversion
MDedge Neurology
Phenytoin May Offer Neuroprotection to Patients With Optic Neuritis
MDedge Neurology
Proposal Requires Three Lesions for Diagnosis of MS
MDedge Neurology
L-Selectin May Not Predict PML Risk Accurately
MDedge Neurology
Study examines efficacy of small group programs for fatigue in MS
MDedge Neurology
BENEFIT 11: No new safety signals with interferon beta-1b
MDedge Neurology
High coffee consumption linked to decreased risk for MS
MDedge Neurology
Evidence builds for mesenchymal stem cell therapy in MS
MDedge Neurology

Related Articles